MIRD 手册第 31 号:MIRDcell V4 人工智能工具用于制定优化放射性药物治疗鸡尾酒方案
该手册介绍 MIRDcell V4 软件中基于序列最小二乘规划算法的人工智能工具,可优化放射性药物鸡尾酒方案以最小化达到给定肿瘤细胞存活分数所需的总衰变数。工具用模型数据、流式细胞术单细胞悬液数据和球体三维时空动力学数据测试,显示双药组合较最佳单药所需衰变数减少。
要点
- MIRDcell V4 的 AI 工具基于序列最小二乘规划算法优化放射性药物鸡尾酒的摩尔活度。
- 在 MDA-MB-231 细胞单细胞悬液中,2 种 211At 抗体组合较最佳单抗体所需 211At 衰变数减少至 1.6 分之一。
- 在假设多细胞团簇中,2 种 195mPt 标记药物组合所需衰变数较任一单药少 1.7 倍。
核心结论
- MIRDcell AI 工具可确定达到给定存活分数所需的优化药物组合及相应摩尔活度。
- 该方法可用于分析来自细胞培养、动物或患者的细胞样本,以预测最大治疗效果且总衰变数最少的药物组合。
研究设计与样本
- 研究为软件工具开发与方法学描述,在 MIRDcell V4 中基于序列最小二乘规划算法构建优化器。
- 工具针对不交叉照射的细胞群体(如循环或播散肿瘤细胞)和多细胞团簇(如微转移灶)提供。
- 工具用模型数据、荧光色素标记抗体标记的单细胞悬液流式细胞术数据以及荧光色素负载脂质体的球体三维时空动力学数据测试。
主要发现
- 在 MDA-MB-231 人乳腺癌细胞单细胞悬液中,考虑 4 种 211At 抗体的实验结合分布,2 药组合较最佳单抗体所需 211At 衰变数减少至 1.6 分之一。
- 另一项研究中,2 种 195mPt 放射性标记药物在假设多细胞团簇中各自呈对数正态分布,2 药组合所需衰变数较任一单药少 1.7 倍。
- 2 种 225Ac 标记药物在球体中提供不同径向分布时,所需衰变数约为最佳单药所需的一半。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiopharmaceutical cocktails have been developed over the years to treat cancer. Cocktails of agents are attractive because 1 radiopharmaceutical is unlikely to have the desired therapeutic effect because of nonuniform uptake by the targeted cells. Therefore, multiple radiopharmaceuticals targeting different receptors on a cell is warranted. However, past implementations in vivo have not met with convincing results because of the absence of optimization strategies. Here we present artificial intelligence (AI) tools housed in a new version of our software platform, MIRDcell V4, that optimize a cocktail of radiopharmaceuticals by minimizing the total disintegrations needed to achieve a given surviving fraction (SF) of tumor cells. Methods: AI tools are developed within MIRDcell V4 using an optimizer based on the sequential least-squares programming algorithm. The algorithm determines the molar activities for each drug in the cocktail that minimize the total disintegrations required to achieve a specified SF. Tools are provided for populations of cells that do not cross-irradiate (e.g., circulating or disseminated tumor cells) and for multicellular clusters (e.g., micrometastases). The tools were tested using model data, flow cytometry data for suspensions of single cells labeled with fluorochrome-labeled antibodies, and 3-dimensional spatiotemporal kinetics in spheroids for fluorochrome-loaded liposomes. Results: Experimental binding distributions of 4 211At-antibodies were considered for treating suspensions of MDA-MB-231 human breast cancer cells. A 2-drug combination reduced the number of 211At decays required by a factor of 1.6 relative to the best single antibody. In another study, 2 radiopharmaceuticals radiolabeled with 195mPt were each distributed lognormally in a hypothetical multicellular cluster. Here, the 2-drug combination required 1.7-fold fewer decays than did either drug alone. Finally, 2 225Ac-labeled drugs that provide different radial distributions within a spheroid require about one half of the disintegrations required by the best single agent. Conclusion: The MIRDcell AI tools determine optimized drug combinations and corresponding molar activities needed to achieve a given SF. This approach could be used to analyze a sample of cells obtained from cell culture, animal, or patient to predict the best combination of drugs for maximum therapeutic effect with the least total disintegrations.
引用
- Katugampola S, Wang J, Howell RW, et al. MIRD Pamphlet No. 31: MIRDcell V4-Artificial Intelligence Tools to Formulate Optimized Radiopharmaceutical Cocktails for Therapy. J Nucl Med. 2024. PMID: 39448267. doi:10.2967/jnumed.123.267238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。